HUTCHMED

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which�

Director’s Share Dealing

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Monthly Return

Total Voting Right

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Interim Report 2023

Next Day Disclosure Return

Exercise of Share Options by a Director

Monthly Return

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED Announces Changes to Board of Directors and Technical Committee

List of Directors and Their Roles and Functions

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Monthly Return

Blocklisting Six Monthly Return

HUTCHMED to Announce 2023 Half-Year Financial Results

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

Monthly Return

Total Voting Rights

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

Standard form for notification of major holdings

List of Directors and Their Roles and Functions

Annual General Meeting held on May 12, 2023 – Poll Results

HUTCHMED Announces Board of Directors and Board Committee Membership

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

Monthly Return

Total Voting Rights

Vesting of awards under the Long Term Incentive Plan

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

2022 Annual Report and Notice of Annual General Meeting

Intended Retirement of Independent Non-executive Director

Monthly Return

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

Total Voting Rights

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

Director’s Share Dealing

Vesting of awards under the Long Term Incentive Plan

Monthly Return

Publication of Form 20-F

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates